Search results for "kinetic"

showing 10 items of 3064 documents

Abstract OT1-08-04: A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients w…

2020

Abstract Background: Activating mutations in PIK3CA, encoding the p110α subunit of phosphatidylinositol 3-kinase (PI3K), are highly prevalent in breast cancer and solid tumor malignancies. GDC-0077 is a potent p110α-selective inhibitor with a novel mechanism of action that degrades mutant p110α and anti-tumor activity in PIK3CA-mutant breast cancer xenograft models as a single agent and in combination with anti-estrogens with or without a CDK4/6 inhibitor. An open-label, Phase I dose-escalation study of GDC-0077 monotherapy and GDC-0077 combined with endocrine therapies and palbociclib is underway in patients (pts) with locally advanced or metastatic PIK3CA-mutant solid tumors. Data from th…

0301 basic medicineCancer Researchmedicine.medical_specialtyCumulative dosebusiness.industryColorectal cancerCmaxPalbociclibmedicine.diseaseGastroenterology03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerOncologyPharmacokinetics030220 oncology & carcinogenesisPharmacodynamicsInternal medicineMedicinebusinessAdverse effectCancer Research
researchProduct

Abstract P1-19-46: A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (…

2020

Abstract Background: Dysregulation of the PI3K/AKT/mTOR signaling pathway occurs in solid tumor malignancies. GDC-0077 (G) is a potent p110α-selective, p110α-mutant degrading inhibitor with anti-tumor activity in PIK3CA-mutant breast cancer xenograft models as a single agent and in combination with endocrine therapies (ET) with or without a CDK4/6 inhibitor (i). An open-label, Phase I dose escalation study of Galone and in combination with ET and P is underway in patients (pts) with locally advanced or metastatic PIK3CA-mutant solid tumors. Data from the combinations of G and L with and without P in pts with PIK3CA-mutant HR+/HER2- breast cancer are presented herein. Methods: This study (NC…

0301 basic medicineCancer Researchmedicine.medical_specialtymedicine.medical_treatmentmacromolecular substancesPalbociclibNeutropeniaGastroenterology03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicineotorhinolaryngologic diseasesmedicineDexamethasoneChemotherapybusiness.industryLetrozolemedicine.diseaseHypokalemia030104 developmental biologyOncology030220 oncology & carcinogenesisPharmacodynamicsmedicine.symptombusinessmedicine.drugCancer Research
researchProduct

Organization into Higher Ordered Ring Structures Counteracts Membrane Binding of IM30, a Protein Associated with Inner Membranes in Chloroplasts and …

2016

The IM30 (inner membrane-associated protein of 30 kDa), also known as the Vipp1 (vesicle-inducing protein in plastids 1), has a crucial role in thylakoid membrane biogenesis and maintenance. Recent results suggest that the protein binds peripherally to membranes containing negatively charged lipids. However, although IM30 monomers interact and assemble into large oligomeric ring complexes with different numbers of monomers, it is still an open question whether ring formation is crucial for membrane interaction. Here we show that binding of IM30 rings to negatively charged phosphatidylglycerol membrane surfaces results in a higher ordered membrane state, both in the head group and in the inn…

0301 basic medicineChloroplastsMembrane lipids02 engineering and technologyBiologyBiochemistryThylakoids03 medical and health scienceschemistry.chemical_compoundMembrane LipidsBacterial ProteinsMembrane BiologyLipid bilayerProtein Structure QuaternaryMolecular BiologyPhosphatidylglycerolSynechocystisMembrane ProteinsBiological membranePhosphatidylglycerolsCell BiologySurface Plasmon Resonance021001 nanoscience & nanotechnologyKinetics030104 developmental biologyMembranechemistryBiochemistryMembrane proteinThylakoidMembrane biogenesisBiophysicsMutant ProteinsProtein Multimerization0210 nano-technologyProtein BindingThe Journal of biological chemistry
researchProduct

Pharmacokinetics of anidulafungin during venovenous extracorporeal membrane oxygenation

2016

Echinocandins are currently considered the first-line treatment for invasive candidiasis (IC) in the intensive care unit (ICU) [1, 2]. However, extracorporeal membrane oxygenation (ECMO), a rescue therapy used in patients with severe acute respiratory distress syndrome (ARDS) [3], could alter the pharmacokinetics of certain drugs [4]. We prescribed anidulafungin for suspected IC in a patient with severe ARDS on ECMO and measured the plasma concentrations of the drug using high-performance liquid chromatography (HPLC).

0301 basic medicineDrugARDSLettermedia_common.quotation_subjectmedicine.medical_treatment030106 microbiologyCritical Care and Intensive Care Medicinelaw.invention03 medical and health sciencesEchinocandins0302 clinical medicinePharmacokineticsRescue therapylawHemofiltrationExtracorporeal membrane oxygenationMedicine030212 general & internal medicinemedia_commonExtracorporeal membrane oxygenationAcute respiratory distress syndromebusiness.industrymedicine.diseaseIntensive care unitAnesthesiaAnidulafunginbusinessmedicine.drugCritical Care
researchProduct

A Physiology-Based Model of Human Bile Acid Metabolism for Predicting Bile Acid Tissue Levels After Drug Administration in Healthy Subjects and BRIC …

2019

Drug-induced liver injury (DILI) is a matter of concern in the course of drug development and patient safety, often leading to discontinuation of drug-development programs or early withdrawal of drugs from market. Hepatocellular toxicity or impairment of bile acid (BA) metabolism, known as cholestasis, are the two clinical forms of DILI. Whole-body physiology-based modelling allows a mechanistic investigation of the physiological processes leading to cholestasis in man. Objectives of the present study were: (1) the development of a physiology-based model of the human BA metabolism, (2) population-based model validation and characterisation, and (3) the prediction and quantification of alter…

0301 basic medicineEXPRESSIONPBPKLIVERmedicine.drug_classPhysiologyBenign Recurrent Intrahepatic CholestasisPopulationBIOMARKERScomputational modellingPhysiologyDIAGNOSISlcsh:Physiology03 medical and health scienceschemistry.chemical_compoundPHARMACOKINETIC MODEL0302 clinical medicineCholestasisPhysiology (medical)Glycochenodeoxycholic acidMedicineddc:610educationEnterohepatic circulationKINETICSOriginal ResearchLiver injuryINTRAHEPATIC CHOLESTASISbile acidseducation.field_of_studyBile acidlcsh:QP1-981business.industryBRIC type 2medicine.diseaseTRANSPORTERS3. Good health030104 developmental biologychemistryToxicitySIMULATION030211 gastroenterology & hepatologyENTEROHEPATIC CIRCULATIONDILIbusinesscholestasisFrontiers in Physiology
researchProduct

A Pharmacological Update of Ellagic Acid.

2018

Este artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-0633-9492.pdf This is a pre-print of an article published in Ríos, JL., Giner, RM., Marín, M. and Recio, MC. (2018). A pharmacological update of ellagic acid. Planta Medica, vol. 84, n. 15, pp. 1068-1093. The final authenticated version is available online at: https://doi.org/10.1055/a-0633-9492 Este es el pre-print del siguiente artículo Ríos, JL., Giner, RM., Marín, M. and Recio, MC. (2018). A pharmacological update of ellagic acid. Planta Medica, vol. 84, n. 15, pp. 1068-1093 que se ha publicado de forma definitiva en https://doi.org/10…

0301 basic medicineEllagic acid - Pharmacokinetics.Antioxidantmedicine.medical_treatmentMetaboliteInterleukin-1betaAnti-Inflammatory AgentsPharmaceutical ScienceApoptosisPharmacologyProtective AgentsProteína quinasa.NeuroprotectionAntioxidantsAnalytical Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEllagic AcidGlycationDrug DiscoverymedicineHumansProtein kinases.Cell ProliferationPharmacologyMetabolic SyndromeAldose reductaseInterleukin-6Tumor Necrosis Factor-alphaMetabolismo - Trastornos.Organic ChemistryNF-kappa BLipid metabolismAtherosclerosisEllagic acid - Physiological effect.NeuroprotectionMetabolism disorder030104 developmental biologyComplementary and alternative medicinechemistryÁcido elágico - Efectos fisiológicos.Antioxidantes.Ácido elágico - Farmacocinética.030220 oncology & carcinogenesisMolecular MedicineMetabolism - Disorders.Antioxidants.Ellagic acidPlanta medica
researchProduct

Bioequivalence decision for nanoparticular iron complex drugs for parenteral administration based on their disposition

2017

Although parenteral iron products have been established to medicinal use decades before, their structure and pharmacokinetic properties are not fully characterized yet. With its' second reflection paper on intravenous iron-based nano-colloidal products (EMA/CHMP/SWP/620008/2012) the European Medicine Agency provided an extensive catalogue of methods for quality, non-clinical and pharmacokinetic studies for the comparison of nano-sized iron products to an originator (EMA, 2015). For iron distribution studies, the reflection paper assumed the use of rodents. In our tests, we used a turkey fetus model to investigate time dependent tissue concentrations in pharmacological and toxicological rele…

0301 basic medicineEmbryo NonmammalianTissue concentrationsTurkeyAmylopectinDose dependenceBioequivalencePharmacologyKidneyToxicologyFerric CompoundsGlucaric Acid03 medical and health sciences0302 clinical medicinePharmacokineticsAnimalsDistribution (pharmacology)MedicineIron complexMaltoseFerric Oxide Saccharatedbusiness.industryMyocardiumGeneral MedicineDisposition030104 developmental biologyLiverTherapeutic Equivalency030220 oncology & carcinogenesisModels AnimalNanoparticlesIron-Dextran ComplexbusinessParenteral ironRegulatory Toxicology and Pharmacology
researchProduct

Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates

2016

Locked nucleic acid (LNA) oligonucleotides have been successfully used to efficiently inhibit endogenous small noncoding RNAs in vitro and in vivo. We previously demonstrated that the direct miR-221 inhibition by the novel 13-mer LNA-i-miR-221 induces significant antimyeloma activity and upregulates canonical miR-221 targets in vitro and in vivo. To evaluate the LNA-i-miR-221 pharmacokinetics and pharmacodynamics, novel assays for oligonucleotides quantification in NOD.SCID mice and Cynomolgus monkeys (Macaca fascicularis) plasma, urine and tissues were developed. To this aim, a liquid chromatography/mass spectrometry method, after solid-phase extraction, was used for the detection of LNA-i…

0301 basic medicineEndogenyIn situ hybridizationBiologyPharmacology03 medical and health sciencesPharmacokineticsDownregulation and upregulationIn vivoDrug DiscoveryLocked nucleic acidLNA inhibitormicroRNAOligonucleotidelcsh:RM1-950Cynomolgus monkeysCynomolgus monkeys LNA inhibitor MicroRNA MiRNA therapeutics Multiple myelomamiRNA therapeuticsMolecular biologyIn vitromultiple myelomalcsh:Therapeutics. Pharmacology030104 developmental biologyMolecular MedicineOriginal ArticleErratumMolecular Therapy - Nucleic Acids
researchProduct

Drying parameters greatly affect the destruction of Cronobacter sakazakii and Salmonella Typhimurium in standard buffer and milk

2017

International audience; Salmonella Typhimurium and Cronobacter sakazakii are two foodborne pathogens involved in neonatal infections from milk powder and infant formula. Their ability to survive in low-moisture food and during processing from the decontamination to the dried state is a major issue in food protection. In this work, we studied the effects of the drying process on Salmonella Typhimurium and Cronobacter sakazakii, with the aim of identifying the drying parameters that could promote greater inactivation of these two foodborne pathogens. These two bacteria were dried under different atmospheric relative humidities in milk and phosphate-buffered saline, and the delays in growth re…

0301 basic medicineEnterobacter-sakazakiiSevere dehydrationSalmonellaWater activitySurvivalMicroorganismDesiccation tolerance030106 microbiologyResistanceDrying conditionsLow-moisture foodsInfant formulasBuffersmedicine.disease_causeMicrobiologyMicrobiologyCultivability03 medical and health sciencesCronobacter sakazakiiStrain variabilitymedicineAnimalsFood scienceDesiccationThermal-destructionMicrobial Viabilitybiologybusiness.industry[ SDV.IDA ] Life Sciences [q-bio]/Food engineeringHuman decontaminationFood safetybiology.organism_classificationCronobacter sakazakiiKineticsMilkInfant formulaSalmonella TyphimuriumFood MicrobiologybusinessBacteriaFood ScienceWater activity
researchProduct

Kinetics of vinyl acetate biodegradation by Pseudomonas fluorescens PCM 2123

2018

Abstract The microbial degradation of vinyl acetate (VA) by Pseudomonas fluorescens PCM 2123 strain was studied in both batch and continuous modes. The purpose of the experiments was to determine the kinetic model of the cell growth and biodegradation rate of vinyl acetate (VA), which was the sole carbon and energy source for tested microorganisms. The experiments, carried out in a batch reactor for several initial concentrations of growth substrate in the liquid phase ranging from 18.6 to 373 gsubstrate·m−3 (gs·m−3) made it possible to choose the kinetic model and to estimate its constants. The Haldane inhibitory model with the values of constants: μm = 0.1202 h−1, KS = 17.195 gs·m−3, Ki =…

0301 basic medicineEnvironmental Engineeringbiology030106 microbiologyKineticsPseudomonasPseudomonas fluorescens010501 environmental sciencesBiodegradationbiology.organism_classification01 natural sciencesbatch and continuous cultures03 medical and health scienceschemistry.chemical_compoundchemistrykineticsPseudomonasVinyl acetateBioreactorvinyl acetateEnvironmental ChemistryMicrobial biodegradation0105 earth and related environmental sciencesNuclear chemistryvinyl acetate; Pseudomonas; kinetics; batch and continuous cultures
researchProduct